The polycystic ovary syndrome. Pathogenesis, metabolic implications, and therapeutic approach

Annals of the New York Academy of Sciences

Volumn 816, Issue , 1997, Pages 177-193

  Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; INSULIN; ORAL CONTRACEPTIVE AGENT;

CONFERENCE PAPER; FEMALE; HYPERANDROGENISM; HYPERINSULINEMIA; METABOLIC DISORDER; MORPHOLOGY; NEUROENDOCRINE DISEASE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; STEROIDOGENESIS;

EID: 0030806344     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb52142.x     Document Type: Conference Paper

References (89)

1. DUNAIF, A., J. K. GIVENS, F. HASELTINE & GR. MERRIAM, Eds. 1992. The Polycystic Ovary Syndrome. Mac Blackwell Scientific. Cambridge.
2. POLSON, D. W., J. WADSWORTH, J. ADAMS & S. FRANKS. 1988. Polycystic ovaries - A common finding in normal women. Lancet 870-872.
3. PETERSSON, F., H. FRIES & S. J. NILLIUS. 1973. Epidemiology of secondary amenorrhea. Am. J. Obstet. Gynecol. 117: 80-86.
4. FUTTERWEIT, W., & D. T. KRIEGER. 1979. Pituitary tumors associated with hyperprolactinemia and polycystic ovary disease. Fertil. Steril. 31: 608-613.
5. Dewailly, D., M. C. Vantyghem, C. Lemaire, F. Duffose, A. Racadot & P. Fossati. 1988. Screening for 21-hydroxylase deficiency among hirsutise women: Lack of utility of the adrenocorticotropin hormone test. Fertil. Steril. 50: 228-232.
6. LEVIN, J. H., E. CARMINA & R. A. LOBO. 1991. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia? Fertil. Steril. 56: 635-640.
7. FRANKS, S. 1989. Polycystic ovary syndrome: A changing perspective. Clin. Endocrinol. 31: 87-120.
8. CONWAY, G. S., J. W. HONOUR & H. S. JACOBS. 1989. Heterogeneity of the polycystic ovary syndrome. Clin. Endocrinol. 30: 459-470.
9. ODriscoll, J. B., H. Mamtora, J. Higginson, A. Pollock, J. Kane & D. C. Anderson. 1994. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients with hirsutism or androgenic alopecia. Clin. Endocrinol. 41: 231-236.
10. PANG, S., B. SOFTNESS, W. SWEENEY & M. I. NEW. 1987. Hirsutism, polycystic ovarian disease and ovarian 17-ketosteroid reductase deficiency. N. Engl. J. Med. 316: 1295-1301.
11. CLAYTON, R. N., V. OGDEN, J. HODGKINSON, L. WORSWICK, D. A. RODIN, S. DYER & T. W. MEADE. 1992. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin. Endocrinol. 37: 127-134.
12. VENTUROLI, S., E. PORU, R. FABBRI, O. MAGRINI, L. GAMMI, R. PARADISI, M. FORACCI, et al. 1988. Episodic pulsative secretion of FSH, LH, prolactin, oestradiol, oestrone and LH circadian variations in polycystic ovary syndrome. Clin. Endocrinol. 28: 93-107.
13. CHRISTMAN, G. M., J. F. RANDOLPH, R. P. KELCH & J. C. MARSHALL. 1991. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 72: 1278-1285.
14. BLANKSTEIN, J., J. RABINOVICI, M. GOLDENBERG, J. SHALEY, A. MEHTA, D. M. SERR & S. MASHIACH. 1987. Changing pituitary reactivity to follicle-stimulating hormone and luteinizing hormone-releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 65: 1164-1167.
15. CUMMING, D. C., R. L. REID, M. E. QUIGLEY, R. W. REBAR & S. S. C. YEN. 1984. Evidence for decreased endogenous dopamine and opoid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin. Endocrinol. 20: 643-648.
16. BARNES, R. & R. A. LOBO. 1985. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J. Clin. Endocrinol. Metab. 61: 779-782.
17. BARNES, R. B., G. N. MIELEIKOWSKY, K. Y. CHA, C. A. SPENCER & R. A. LOBO. 1986. Effects of dopamine and metoclopramide in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 63: 506-509.
18. MCKENNA, T. J. 1988. Current concepts: Pathogenesis and treatment of polycystic ovary syndrome. N. Engl. J. Med. 318: 558-562.
19. CHANG, R. J., F. P. MANFDEL, J. K. LU & H. L. JUDD. 1982. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 60: 773-778.
20. DUNAIF, A., C. LOONGCOPE, J. CANICK, T. BADGER & W. F. CROWLY, JR. 1985. The effects of the aromatase inhibitor delta-testosterone on gonadotropin release and steroid metabolism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 60: 773-780.
21. YOUNG, J. R. & R. B. JAFFE. 1976. Strength-duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. J. Clin. Endocrinol. Metab. 42: 432-442.
22. ROSENFIELD, R. L. 1985. Congenital adrenal hyperplasia and reproductive function in females. In Adolescence in Females. C. Flamigni, S. Venruroli & J. Givens, Eds.: 373-387. Year Book Medical Publishers. Chicago.
23. SERAFINI, P., P. D. SILLV, R. J. PAULSEN, M. EKIND-HERNANDEZ & R. A. LOBO. 1986. Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women. Am. J. Obstet. Gynecol. 155: 1288-1292.
24. DUNAIF, A. 1986. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? J. Clin. Endocrinol. Metab. 63: 215-221.
25. DIAMANTI, E., N. KAKLAS, E. GEORGIADOU, J. SPINA, D. RANGOU & C. CHLOUVERAKIS. 1992. Intraovarian regulators and polycystic ovary syndrome. The effect of an androgen receptor blocker on gonadotropin release and androgen levels in PCO. Satellite symposium of the 9th International Congress of Endocrinology tr. No. 106.
26. DIAMANTI-KANDARAKIS, E., A. MITRAKOU, M. I. MAGDA, D. P. HENNES, N. KAKLAS, J. SPINA, E. GEORGIADOU, R. G. HUFFMAN, A. H. KISSEBACH & S. RAPTIS. 1995. Insulin sensitivity and androgens therapy in women with polycystic ovary syndrome. Metabolism 44: 525-531.
27. ERICKSON, G. F. & S. S. C. YEN. 1984. New data on follicle cells hi polycystic ovaries: A proposed mechanism for the genesis of cystic follicles. Semin. Reprod. Endocrinol. 2: 231.
28. ERICKSON, G. 1986. An analysis of follicle development and ovum maturation. Ser. Reprod. Endocrinol. 4: 233-254.
29. FUTTERWEIT, W. 1984. Hyperprolactinemia and polycystic ovarian disease. In Polycystic Ovarian Disease. W. Futterwit, Ed.: 97-111. Springer-Verlag. New York.
30. ERICKSON, G. F., D. A. MAGOFFIN, C. A. DYER & C. HOFEDITZ. 1985. The ovarian androgen producing cells: A review of structure/function relationships. Endocrinol. Rev. 6: 371-399.
31. POLSON, D. W., S. FRANKS, M. J. REED, R. W. CHENG, J. ADAMS & V. H. JAMES. 1987. The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries. Clin. Endocrinol. 26: 581-588.
32. ERICKSON, G. F. 1992. Folliculogenesis in polycystic ovary syndrome. In Current Issues in Endocrinology and Metabolism: Polycystic Ovary Syndrome. A. Dunaif, J. Givens, F. Haseltine & G. Merrlan, Eds. Blackwell Scientific. Cambridge, MA.
33. ERICKSON, G. F., V. G. GARZO & D. A. MAGOFFIN. 1989. Insulin-like growth factor 1 regulates aromatase activity in human granulosa and granulosa luteal cells. J. Clin. Endocrinol. Metab. 69: 716-724.
34. ERICKSON, G. F., A. J. HSUEH, M. E. QUIGLLEY, R. W. RADAR & S. S. YEN. 1979. Functional studies of aromase activity in human granulosa cells from normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 49: 514-519.
35. FRANKS, S. & H. D. MASON. 1991. Polycystic ovary syndrome: Interaction of follicle stimulating hormone and polypeptide growth factors in oestradiol production by human granulosa cells. J. Steroid Biochem. Mol. Biol. 40: 405-409.
36. CONTE, F. A., M. M. GRUMBACH, Y. ITO, C. R. FISHER & E. R. SIMPSON. 1994. A syndrome of female pseudohermaphroditism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450). J. Clin. Endocrinol. Metab. 78: 1287-1292.
37. SHERMAN, A. I. & S. BROWN. 1979. The precursors of endometrial carcinoma. Am. J. Obstet. Gynecol. 135: 947-956.
38. HILLIER, S. G. & G. T. Ross. 1979. Effects of exogenous testosterone on ovarian weight, follicular morphology and intraovarian progesterone concentration in estrogen-primed hypophysectomised immature female rats. Bil. Reprod. 20: 61-68.
39. HUFFMAN, F. & C. MEGER. 1965. On the action of intraovarian injection of androgen on follicle and corpus luteum maturation in women. Geburst. Frauenheik. 25: 1132-1137.
40. PANG, S., B. SOFTNESS, W. SWEENEY & M. I. NEW. 1987. Hirsutism, polycystic ovarian disease and ovarian 17-ketosteroid reductase deficiency. N. Engl. J. Med. 316: 1295-1301.
41. RHEAUME, E., Y. LACHANCE, H-F. ZHAO, N. BRETON, M. DUMONT, Y. DE LAUNOIT, C. TRUDEL, V. LUU-THE, J. SIMARD & F. LABRIE. 1991. Structure and expression of a new complementary DNA encoding the almost exclusive 3b-hydroxysteroid dehydrogenase/D5-D4 isomerase in human adrenals and gonads. Mol. Endocrinol. 5: 1147-1157.
42. ROSEFIELD, R. L., R. B. BARNES, J. F. CARA & A. W. LUCKY. 1990. Dysregulation of cytochrome P450c 17 alpha as the case of polycystic ovarian syndrome. Fertil. Steril. 53: 785-791.
43. WHITE, D., A. LEIGH, C. WILSON, A. DONALSON & C. FRANKS. 1995. Gonadotropin and gonadal steroid response to a dose of long-acting agonist of gonadotropin releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin. Endocrinol. 42: 475-481.
44. VOUTILAINEN, R., J. TAPANAINEN, B-C. CHUNG, K. J. MATTESON & W. L. MILLER. 1986. Hormonal regulation of P450 scc(20- 22-desmolase) and P450c17(17α-hydroxylase/17,20-lyase) in cultures human granulosa cell. J. Clin. Endocrinol. Metab. 63: 202-207.
45. EHRMANN, D. A., R. L. ROSENFIELD, R. BARNES, D. F. BRIGELL & Z. SHEIKH. 1992. Detection of functional ovarian hyperandrogenism in women with androgen excess. N. Engl. J. Med. 327: 157-162.
46. ROSENFILD, R. L., R. B. BARNES & D. A. EHRMANN. 1994. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin releasing hormone agonist challenge in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 79: 1686-1692.
47. ROSENFILD, R. L., R. B. BARNES & D. A. EHRMAN. 1994. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin releasing hormone agonist challenge in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 79: 1686-1692.
48. GILING-SMITH, C., D. S. WILIS, R. W. BEARD & S. FRANKS. 1994. Hypersecretion of androstenedione by isolated cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 79: 1158-1165.
49. CONWAY, G. S., J. W. HONOUR & H. S. JACOBS. 1989. Heterogeneity of the polycystic ovary syndrome. Clin. Endocrinol. 30: 459-470.
50. LOBO, R. A. 1991. Hirsutism in polycystic ovary syndrome: Current concepts. Clin. Obstet. Gynecol. 34: 817-826.
51. BARDIN, C. W. & M. B. LIPSETT. 1967. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J. Clin. Invest. 46: 891-902.
52. ADERSON, D. C. 1974. Sex-hormone-binding-globulin. Clin. Endocrinol. 3: 69-96.
53. PUGEAT, M., J. C. CRAVE, M. ELMIDANI, et al. 1991. Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin. J. Steroid Biochem. Mol. Biol. 40: 841-849.
54. BURGEN, G. A., J. R. GIVENS & A. E. KITABCHI. 1980. Correlation of hyperandrogenism with hyperinsulism in polycystic ovarian disease. J. Clin. Endocrinol. Metab. 50: 113-116.
55. DUNAIF, A. 1993. Insulin resistance in polycystic ovarian syndrome. Ann. N.Y. Acad. Sci. 687: 60-64.
56. KING, H. & M. REWERS. 1993. Global estimates or prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 16: 157-177.
57. HARRIS, M. I., W. C. HADDEN, W. C. KWOLER & P. H. BENNETT. 1987. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36: 523-534.
58. DUNAIF, A., M. GRAF, J. MANDELI, V. LAUMAS &; A. DOBJANSKI. 1987. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J. Endocrinol. Metab. 65: 499-507.
59. DUNAIF, A., W. FUTTERWEIT, K. R. SEGAL & A. DOBRJANSKY. 1989. Profound peripheral insulin resistance, independentn of obesity, in the polycystic ovary syndrome. Diabetes 38: 1165-1174.
60. OVESEN, R., J. MOLLER, H. J. INGERSELEV, J. O. L. JORGENSEN, A. MENGEL, Q. SCHMITZ, K. G. M. M. ALBERTI & N. MOLER. 1993. Normal basal and insulin-stimulated fuel metabolism in lean women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 77: 1636-1640.
61. OMeara, N. M., J. D. Blackman, D. A. Ehrmann, R. B. Barnes, J. B. Jaspan, R. L. Rosenfield & K. S. Polonsky. 1993. Defects in b-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76: 1241-1247.
62. DE FRONZO, R. A., J. D. TOBIN & R. ANDRES. 1979. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol. 237: E214-223.
63. DIAMANTI-KANDARAKIS, E., A. MIRTRAKOU, D. PLATANISSIOTIS, G. SPINA, E. DYTELIS, S. PAPTIS. (Sponsor: S. Nader). 1994. Polycystic ovary syndrome: A model of primary defect of insulin action. First and second Department of Medicine, University of Athens Medical School, Greece. Abstract No. 834. 76th Annual Meeting Endocrine Society, Anaheim, CA.
64. DUNAIF, A. & D. FINEGOOD. 1996. b-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81: 3.942-3.947.
65. ERRHMAN, D. A., R. B. BARNES & R. L. ROSENFILD. 1995. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endoc. Rev. 16: 322-353.
66. GARALDI, T. P., A. EL-ROEIY, Z. MADAR, D. REICHART, J. M. OLEFSKY & S. S. C. YEN. 1992. Cellular mechanisms of insulin resistance on polycystic ovarian syndrome. J. Clin. Endocrinol. Metabol. 75: 577-583.
67. ROSENBAUM, D., R. S. HABER & A. DUNAIF. 1993. Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporters in adipocytes. Am. J. Physiol. 264: 197-202.
68. DUNAIF, A., J. XIA, C-B. BOOK, E. SCHENKER & Z. TANG. 1995. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: A potential mechanism for insulin resistance in the polycystic ovary syndrome. J. Clin. Invest. 96: 801-810.
69. KAHN, C. R., J. S. FLIER, R. S. BAR, J. A. ARCHER, P. GORDEN, M. M. MARTIN & J. ROTH. 1976. The syndromes of insulin resistance and acanthosis nigricans. N. Engl. J. Med. 294: 739-745.
70. NESTLER, J. E., C. O. BARLASCINI, D. W. MATT, et al. 1989. Suppression of serum insulin by diazoxide reduces testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 68: 1027.
71. VELAZGUEZ, E. M., S. MENTOZA, T. HAMER, F. SOSA & C. J. GLUECK. 1994. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647-654.
72. DUNAIF, A., G. GREEN, W. FUTTERWEIT & A. DOBRJANSKY. 1990. Suppression of hyperandrogenism does not improve peripheral of hepatic insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 70: 699-704.
73. MOGHETTI, P., F. TOSI, R. CASTELLO, et al. Antiandrogens and insulin action. J. Clin. Endocrinol. Metab. In press.
74. POLDERMAN, K. H., J. K. GOOREN, H. ASSCHERMAN, A. BARKER & R. J. HEINE. 1994. In-duction of insulin resistance by androgens and estrogens. J. Clin. Endocrinol. Metab. 79: 265-271.
75. BARBIERI, R. L. 1992. Effects of insulin on ovarian steroidogenesis. In Polycystic Ovary Syndrome. A. Dunaif, J. H. Givens, F. P. Haseline, et al., Eds. Blackwell Scientific. Cambridge, MA.
76. ADASHI, E. Y. 1993. Intraovarian regulation: The proposed role of insulin-like growth factors. Ann. N.Y. Acad. Sci. 687: 10-12.
77. NESTLER, J. E., J. N. CLORE & W. G. BLACKARD. 1992. Effects of insulin on steroidogenesis in vivo. In Polycystic Ovary Syndrome. A. Dunaif, J. R. Givens, F. P. Halestine, G. R. Merriam, Eds.: 265-278. Blackwell Scientific. Oxford, England.
78. HAGUE, W. M., J. ADAMS, S. T. REEDERS, T. E. A. PETO & H. S. JACOBS. 1988. Familial polycystic ovaries: A genetic disease? Clin. Endocrinol. 29: 593-605.
79. CAREY, A. H., K. L. CHAN, F. SHORT, D. WHITE, R. WILLIAMSON & S. FRANKS. 1993. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin. Endocrinol. 38: 653-658.
80. SORBARA, L., D. WEISS, R. DELSON, C. RICHARDS, A. DOBRJANSKY & A. DUNAIF. 1991. Polycystic ovary syndrome, ethnicity and insulin action. 14th IDF Congress Satellite on Epidemiology of Diabetes. Williamsburg, VA. Abstr.
81. ZHANG, L., H. RODRIGUEZ, S. OHNO, et al. 1995. Serine phosphorylation of human P450c17 increase 17,20 lyase activity: Implications for adrenarche and polycystic ovary syndrome. Proc. Natl. Acad. Sci. USA 92: 10619-10623.
82. VERMULEN, A. & R. RUBENS. 1988. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception (USA) 38: 419-428.
83. EARTH, J. H., C. A. CHERRY, F. WOJNAROWSKA & R. P. DAWER. 1989. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women. J. Clin. Endocrinol. Metab. 68: 966-970.
84. CUSAN, L., J. L. DUPOND, R. R. GOMEZ, TREMBLAY & F. LABRIE. 1994. Comparison of flutamide and Spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil. Steril. 61: 281-287.
85. ADASHI, E. Y. 1986. Clomiphene citrate-induced ovulation: Aclinical update. Semin. Reprod. Endocrinol. 4: 255-275.
86. HOFMAN, C. A., C. W. EDWARDS III, R. M. HILMAN & J. R. COLCA. 1992. Treatment of insulin-resistant mice with oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and prosphoenolpyruvate carboxykinase expression. Endocrinology 130: 735-740.
87. KIDDY, D. S., D. HAMILTON FAIRLEY, A. BUSH, F. SHORT, V. ANYAKOU, M. J. REED & S. FRANKS. 1992. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. 36: 105-111.
88. GEOFFREY, P. R. 1995. Androgenic disorders of women: Diagnostic and therapeutic decision making. Am. J. Med. Assoc. 98: 120-129s.
89. DIAMANTI-KANDARAKIS, E., CH. KOULI & G. TOLIS. 1996. Therapeutic effect of Metformin on insulin resistance and hyperandrogenism in the polycystic ovary syndrome(PCO). Abstr. No. P-808. Proceedings of the 10th International Congress of Endocrinology (ICE '96). San Francisco, CA.